<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">AMB</journal-id><journal-title-group><journal-title>Advances in Microbiology</journal-title></journal-title-group><issn pub-type="epub">2327-0810</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/AMB.2020.94021</article-id><article-id pub-id-type="publisher-id">AMB-39101</article-id><article-categories><subj-group subj-group-type="heading"><subject>AMB20200400000_61925557.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>生命科学</subject></subj-group></article-categories><title-group><article-title>
 
 
  肠道菌群与肿瘤的相关研究进展
  Research Progress of Intestinal Flora and Tumor
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>黎</surname><given-names>雨晴</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>兴玉</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>未希</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>周</surname><given-names>芳美</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>浙江中医药大学医学技术学院，浙江 杭州</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>10</day><month>12</month><year>2020</year></pub-date><volume>09</volume><issue>04</issue><fpage>156</fpage><lpage>163</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    肠道菌群是人体肠道的微生物，因其数量的庞大有着“人体的第二基因组”之称。这些细菌在人体内相互作用，与人类相互作用，对维持人体健康发挥着重要的作用，而当肠道菌群数量与种类的平衡被打破，机体会出现肠道菌群失调，进而引发肿瘤在内的一系列疾病严重威胁人类健康。研究发现，肠道菌群与恶性肿瘤的发生、发展、治疗效果等密切相关。本文回顾了近年来肠道菌群与肿瘤的相关研究进展，并对未来肠道菌群于肿瘤的发展趋势做出展望，为肿瘤的进一步治疗提供理论依据。
    Intestinal microflora is the microorganism of human intestinal tract, which is called “the second genome of human body” because of its large number. These bacteria interact in the human body and interact with human beings, which plays an important role in maintaining human health. However, when the balance between the number and species of intestinal flora is broken, the body will have intestinal flora imbalance, which will lead to a series of diseases including cancer, which seriously threaten human health. Studies have found that intestinal flora is closely related to the occurrence, development and therapeutic effect of malignant tumors. In this paper, we reviewed the research progress of intestinal flora and tumor in recent years, and prospected the development trend of intestinal flora in tumor in the future, and provided theoretical basis for further treatment of tumor. 
   
   
    
  
 
</p></abstract><kwd-group><kwd>肠道菌群，肿瘤，发生机制，治疗, Intestinal Flora</kwd><kwd> Tumor</kwd><kwd> Pathogenesis</kwd><kwd> Treatment</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>肠道菌群是人体肠道的微生物，因其数量的庞大有着“人体的第二基因组”之称。这些细菌在人体内相互作用，与人类相互作用，对维持人体健康发挥着重要的作用，而当肠道菌群数量与种类的平衡被打破，机体会出现肠道菌群失调，进而引发肿瘤在内的一系列疾病严重威胁人类健康。研究发现，肠道菌群与恶性肿瘤的发生、发展、治疗效果等密切相关。本文回顾了近年来肠道菌群与肿瘤的相关研究进展，并对未来肠道菌群于肿瘤的发展趋势做出展望，为肿瘤的进一步治疗提供理论依据。</p></sec><sec id="s2"><title>关键词</title><p>肠道菌群，肿瘤，发生机制，治疗</p></sec><sec id="s3"><title>Research Progress of Intestinal Flora and Tumor</title><p>Yuqing Li, Xingyu Yang, Weixi Wang, Fangmei Zhou<sup>*</sup></p><p>College of Medical Technology, Zhejiang Chinese Medicine University, Hangzhou Zhejiang</p><p><img src="//html.hanspub.org/file/2-2730188x4_hanspub.png" /></p><p>Received: Nov. 15<sup>th</sup>, 2020; accepted: Dec. 3<sup>rd</sup>, 2020; published: Dec. 10<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/2-2730188x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Intestinal microflora is the microorganism of human intestinal tract, which is called “the second genome of human body” because of its large number. These bacteria interact in the human body and interact with human beings, which plays an important role in maintaining human health. However, when the balance between the number and species of intestinal flora is broken, the body will have intestinal flora imbalance, which will lead to a series of diseases including cancer, which seriously threaten human health. Studies have found that intestinal flora is closely related to the occurrence, development and therapeutic effect of malignant tumors. In this paper, we reviewed the research progress of intestinal flora and tumor in recent years, and prospected the development trend of intestinal flora in tumor in the future, and provided theoretical basis for further treatment of tumor.</p><p>Keywords:Intestinal Flora, Tumor, Pathogenesis, Treatment</p><disp-formula id="hanspub.39101-formula11"><graphic xlink:href="//html.hanspub.org/file/2-2730188x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/2-2730188x8_hanspub.png" /> <img src="//html.hanspub.org/file/2-2730188x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>人体肠道是复杂多样的微生物群落的所在地 [<xref ref-type="bibr" rid="hanspub.39101-ref1">1</xref>]，是一个菌种密集的微生物生态系统 [<xref ref-type="bibr" rid="hanspub.39101-ref2">2</xref>]。近年来，随着分子方法的发展，特别是基因组学技术的进步促进了科学家们对该微生物群落的遗传和代谢特征进行大规模的分析，使我们对人类肠道菌群的认识发生了革命性变化 [<xref ref-type="bibr" rid="hanspub.39101-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.39101-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.39101-ref5">5</xref>]，由此，肠道微生物群及其波动与人体整体健康的关系成为了现代医学研究的热点领域 [<xref ref-type="bibr" rid="hanspub.39101-ref6">6</xref>]。肠道菌群与宿主生活在互相关系中，正常生理状态下，其在胃肠道中起着屏障作用，对维持肠道生态环境的动态平衡以及机体的稳定有着重要的作用；但当宿主与其之间的微妙平衡被破坏，所起的屏障效应就消失，导致肠道菌群紊乱、失调，从而引发包括肿瘤在内的各种疾病 [<xref ref-type="bibr" rid="hanspub.39101-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.39101-ref8">8</xref>]。肿瘤一直是人类健康的巨大威胁，但目前对于肿瘤的诊断、监测以及治疗选择的条件仍然有限，寻找治疗肿瘤的有效方法迫在眉睫 [<xref ref-type="bibr" rid="hanspub.39101-ref9">9</xref>]。本文将从肠道菌群与肿瘤的发生、发展和治疗之间的关系加以综述，为肿瘤的进一步治疗提供理论依据。</p></sec><sec id="s6"><title>2. 肠道菌群影响肿瘤的发生</title><p>肠道菌群利用食物中不易消化的膳食纤维产生一系列复杂的代谢物，其中短链脂肪酸(Short-Chain Fatty Acids, SCFA)对调节肠道内的免疫反应和肿瘤发生起着重要作用。SCFA是一种包括乙酸盐、丙酸盐和丁酸盐等在肠内具有丰富生物活性的物质 [<xref ref-type="bibr" rid="hanspub.39101-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.39101-ref11">11</xref>]，在结直肠癌中起着复杂的作用。丁酸盐可以说是对人类健康最重要的SCFA，Belcheva A等人 [<xref ref-type="bibr" rid="hanspub.39101-ref12">12</xref>] 的研究发现丁酸酯对含抗原提呈细胞(Antigen presenting cells, APC)突变和错配修复基因(MSH 2)缺陷的转基因小鼠具有促肿瘤作用，而Singh N等人 [<xref ref-type="bibr" rid="hanspub.39101-ref13">13</xref>] 的研究结果证明了缺乏丁酸酯受体Grp109a的小鼠因炎症刺激或APC突变而促进了肿瘤发生，为证明APC基因突变或结肠炎小鼠模型中丁酸盐抑制肿瘤的发生提供了证据，还有研究表明丁酸盐通过诱导结肠癌细胞凋亡和通过抑制组蛋白去乙酰化酶调节基因表达而成为人类结肠肌细胞的主要能量来源，也提示其具有潜在的抗癌活性。所以肠道菌群产生的丁酸脂在结直肠癌中起着积极还是消极的作用，还需进一步研究。</p><p>肠道菌群及其代谢能直接诱发癌症。肠道菌群的细菌毒素，如细胞毒性膨胀毒素(Cytolethal distending toxin, CDT)、细胞毒性坏死因子1、脆弱杆菌毒素，以及细菌驱动的硫化氢和超氧自由基，已被鉴定为可引起DNA损伤的致癌物质 [<xref ref-type="bibr" rid="hanspub.39101-ref6">6</xref>]。有学者还发现脆弱的芽孢杆菌可在宿主细胞中产生破坏DNA的基因毒素，改变核仁的结构从而导致肿瘤免疫微环境的改变，引起大肠癌 [<xref ref-type="bibr" rid="hanspub.39101-ref14">14</xref>]。在肝脏胆固醇中生成的少量初级胆汁酸，没有进行肝脏循环，而被肠道细菌代谢，在结肠内生成次生胆汁酸，包括结石胆酸和脱氧胆酸(Deoxycholate-citrate agar，DCA) [<xref ref-type="bibr" rid="hanspub.39101-ref15">15</xref>]，有研究表明，DCA对胃肠器官具有致癌作用 [<xref ref-type="bibr" rid="hanspub.39101-ref16">16</xref>]。综上所述，肠道菌群对肿瘤的发生与发展起着重要的作用。</p></sec><sec id="s7"><title>3. 肠道菌群影响肿瘤发生的机制</title><p>近年来，随着下一代测序技术的出现，科学家们也逐渐认识到肠道菌群不仅会影响肿瘤的发生，而且可能与其进展的具体机制相关 [<xref ref-type="bibr" rid="hanspub.39101-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.39101-ref18">18</xref>]。目前研究发现肠道微生物对恶性肿瘤发生发展的作用机制主要涉及炎症、免疫反应、物质代谢产物和遗传物质改变几个方面 [<xref ref-type="bibr" rid="hanspub.39101-ref19">19</xref>]。表1为肠道菌群影响肿瘤发生的具体机制。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Possible mechanisms of intestinal flora and intestinal neoplasm</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >菌群种类</th><th align="center" valign="middle" >肿瘤名称</th><th align="center" valign="middle" >具体机制</th></tr></thead><tr><td align="center" valign="middle" >乳酸杆菌</td><td align="center" valign="middle" >胰管腺癌</td><td align="center" valign="middle" >持续炎症，调节免疫系统–微生物–肿瘤轴，影响代谢， 改变肿瘤微环境 [<xref ref-type="bibr" rid="hanspub.39101-ref20">20</xref>]</td></tr><tr><td align="center" valign="middle" >幽门螺杆菌</td><td align="center" valign="middle" >胃癌</td><td align="center" valign="middle" >慢性炎症、免疫抑制</td></tr><tr><td align="center" valign="middle" >脆弱芽胞杆菌</td><td align="center" valign="middle" >结直肠癌</td><td align="center" valign="middle" >肠毒素诱导免疫抑制</td></tr><tr><td align="center" valign="middle" >肠肝细菌</td><td align="center" valign="middle" >结直肠癌</td><td align="center" valign="middle" >免疫抑制</td></tr><tr><td align="center" valign="middle" >牛链球菌</td><td align="center" valign="middle" >结直肠癌</td><td align="center" valign="middle" >炎症</td></tr><tr><td align="center" valign="middle" >粪肠球菌</td><td align="center" valign="middle" >结直肠癌</td><td align="center" valign="middle" >与巨噬细胞的互相作用</td></tr><tr><td align="center" valign="middle" >败血梭菌</td><td align="center" valign="middle" >结直肠癌</td><td align="center" valign="middle" >引起肌坏死、慢性粒–单核细胞机制</td></tr><tr><td align="center" valign="middle" >核梭杆菌</td><td align="center" valign="middle" >结直肠癌</td><td align="center" valign="middle" >炎症，肿瘤微环境改变</td></tr><tr><td align="center" valign="middle" >脆弱类杆菌</td><td align="center" valign="middle" >结直肠癌</td><td align="center" valign="middle" >产硫化氢，引起细胞毒性</td></tr></tbody></table></table-wrap><p>表1. 肠道菌群影响肿瘤发生的具体机制</p><sec id="s7_1"><title>3.1. 肠道菌群诱导促炎途径致癌</title><p>肠道菌群形成的炎症环境在促进肿瘤的生长和扩散方面起着重要作用 [<xref ref-type="bibr" rid="hanspub.39101-ref21">21</xref>]。当肠道菌群失调时会诱导肠道炎症体的激活，进而会导致持续的炎症反应以及免疫病理和组织损伤的出现，严重情况下会导致肿瘤的发生 [<xref ref-type="bibr" rid="hanspub.39101-ref22">22</xref>]。具体来说，肠道菌群能够激活人体内的炎症反应，增加促炎细胞和细胞因子的分泌，促发氧化应激，改变能量动力学，破坏DNA，最终促进肿瘤的生长 [<xref ref-type="bibr" rid="hanspub.39101-ref23">23</xref>]。</p><p>肠道菌群与癌症相关的炎症状态有着重要的关系 [<xref ref-type="bibr" rid="hanspub.39101-ref24">24</xref>]。牛链球菌(Streptococcus bovis, SB)是一种肠道内的革兰氏阳性细菌和低度机会病原体，可在人体内引起全身感染，如心内膜炎或细菌血症等症状，由其导致的肠黏膜病变被认为是许多细菌进入全身循环的门户，进而可能诱发癌症 [<xref ref-type="bibr" rid="hanspub.39101-ref25">25</xref>]。幽门螺杆菌在胃和肠中定植，其引起的胃癌致病途径已被充分证明 [<xref ref-type="bibr" rid="hanspub.39101-ref26">26</xref>]，Ganal-Vonarburg SC等人 [<xref ref-type="bibr" rid="hanspub.39101-ref7">7</xref>] 的研究表明，幽门螺杆菌引起的肠道炎症形成后，位于粘膜组织中的先天性淋巴样细胞(Innate lymphoid cells, ILCs)衍生的IL-22作用于上皮细胞并诱导癌症形成。许多研究表明核梭杆菌与结直肠癌的发生有着密切的联系，Aleksandar D. Kostic等人 [<xref ref-type="bibr" rid="hanspub.39101-ref27">27</xref>] 研究发现在ApcMin/+小鼠肠道肿瘤发生模型中，核梭杆菌增加肿瘤的多样性，选择性地招募肿瘤浸润的髓样细胞，产生一个有利于炎症的微环境，促进结直肠癌的发生和发展。</p></sec><sec id="s7_2"><title>3.2. 肠道菌群诱导免疫抑制致癌</title><p>肠道菌群通过各种机制影响免疫系统，免疫系统可能是肠道菌群与肠道肿瘤之间相互作用的关键因素 [<xref ref-type="bibr" rid="hanspub.39101-ref28">28</xref>]。Uribe-Herranz M等人 [<xref ref-type="bibr" rid="hanspub.39101-ref29">29</xref>] 的研究表明缺乏微生物的无菌小鼠产生较少的CD4<sup>+</sup>T细胞，并且浆细胞产生IgA的数量减少，影响宿主的免疫调节作用，提示肠道菌群在免疫系统中有着重要作用。Notch、bmp、wnt、jak/stat和ras等良好的信号通路时维持肠道内稳态所必须的，它们的失调可能会诱导肿瘤的发生。Zhou J等人 [<xref ref-type="bibr" rid="hanspub.39101-ref30">30</xref>] 通过组织特异性bmp信号通路成分的缺失建立了诱导性肿瘤模型，当BMP信号丢失时，会导致JNK/MMP 2信号的异常激活，从而导致肠道屏障功能障碍和肠道菌群失调，失调的微生物群会引发再生反应，并刺激肿瘤的生长。Mizutani S等人 [<xref ref-type="bibr" rid="hanspub.39101-ref16">16</xref>] 的研究结果表明核梭杆菌的FADA蛋白可以与人体内钙依赖性的跨膜蛋白(E-cadherin)结合，FADA-E-cadherin结合体可激活β-catenin信号，参与肿瘤免疫机制的信号转导，促发上皮细胞增殖，加速结直肠癌的发生，引起早期癌变。</p><p>肠道菌群在影响结肠上皮屏障功能中也起着不可或缺的作用。核梭杆菌是肠道内一种重要的厌氧菌，它可以通过参与上皮细胞增殖和肿瘤免疫机制的信号转导途径，促进癌症的发生。Wu S.等人 [<xref ref-type="bibr" rid="hanspub.39101-ref31">31</xref>] 研究发现脆弱的拟杆菌杆菌毒素刺激肠道上皮细胞脱落以及γ-分泌酶依赖性的E-钙粘蛋白裂解，导致细胞通透性增加和β-连环蛋白的活化，随后细胞增殖增加，表明了培养的上皮细胞模型实际上是互补的促癌机制。</p></sec></sec><sec id="s8"><title>4. 肠道菌群影响肿瘤的治疗</title><p>近年来，科学家们已经研究出肠道菌群支持宿主对抗癌症的几种机制，这些机制包括利用肠道菌群进行肿瘤免疫疗法、化学疗法、放射疗法以及其他机制来增强抗癌免疫反应和提高癌症免疫治疗的效果。这一发展领域的进一步研究有望发现更多具有抑瘤特性的微生物代谢物，为治疗肿瘤提供可行的方案 [<xref ref-type="bibr" rid="hanspub.39101-ref32">32</xref>]。</p><sec id="s8_1"><title>4.1. 肠道菌群影响肿瘤免疫治疗</title><p>肠道微生物的变化可以影响机体免疫状态，肠道微生物调控有望成为肿瘤免疫疗法的重要组成部分 [<xref ref-type="bibr" rid="hanspub.39101-ref33">33</xref>]。肠道菌群在免疫治疗后能增强抗肿瘤T细胞反应的潜力，为宿主和微生物之间的相互作用增加了另一个更深的维度 [<xref ref-type="bibr" rid="hanspub.39101-ref17">17</xref>]。肠道微生物对癌症治疗的反应和毒性作用的最早证据之一是用异基因干细胞移植(allo-HSCT)治疗血液恶性肿瘤 [<xref ref-type="bibr" rid="hanspub.39101-ref34">34</xref>]。此后，科学家们积极利用肠道菌群进行肿瘤免疫疗法研究，有科学家推测肠道菌群的易位通过TLR 4信号传导，Iida N等人 [<xref ref-type="bibr" rid="hanspub.39101-ref35">35</xref>] 的研究表明，在一定情况下，肿瘤相关髓系细胞由肠道共菌通过TLR 4信号通路启动，产生TNF和其他炎症细胞因子，介导抗生素等药物的抗肿瘤作用。Gopalakrishnan等人 [<xref ref-type="bibr" rid="hanspub.39101-ref36">36</xref>] 研究发现肠道菌群可能可以调节PD-1免疫治疗对黑色素瘤患者的反应，有良好肠道菌群的病人，可以增加抗原呈递量，增强全身和抗肿瘤免疫反应，改善外周和肿瘤微环境中的效应T细胞功能。</p><p>近年来，肿瘤学的治疗策略因使用免疫检查点阻断抗体而发生了革命性的变化，肠道菌群应用于免疫检查点阻断抗体治疗肿瘤是一个新兴的研究领域 [<xref ref-type="bibr" rid="hanspub.39101-ref11">11</xref>]。2015年，V&#233;tizou M等人 [<xref ref-type="bibr" rid="hanspub.39101-ref37">37</xref>] 在小鼠模型中研究了肠道微生物群对免疫检查点阻断反应的影响，发现了肠道菌群的组成可以影响对针对细胞毒性T淋巴细胞抗原-4(CTLA-4)和程序性死亡受体-1 (PD-1)的免疫检查点抑制剂的反应，为证明CTLA-4阻断剂的抗肿瘤免疫治疗依赖于肠道微生物提供了依据，但患者对这些治疗的反应往往是异质性的，并不持久。许多研究表明，肠道菌群可能通过天然免疫和适应性免疫影响抗肿瘤免疫反应，而且这种治疗反应可以通过它的调节而得到改善 [<xref ref-type="bibr" rid="hanspub.39101-ref36">36</xref>]，但肠道微生物对肺癌患者使用免疫检查点抑制剂治疗有着不同的影响 [<xref ref-type="bibr" rid="hanspub.39101-ref6">6</xref>]，所以对于这一方法还需进一步研究，扩大其在肿瘤患者中的应用。</p></sec><sec id="s8_2"><title>4.2. 肠道菌群影响肿瘤化学治疗</title><p>肠道微生物可通过调节药物疗效，消除抗癌作用和介导毒性作用，在抗癌治疗反应中发挥重要作用 [<xref ref-type="bibr" rid="hanspub.39101-ref38">38</xref>]。化疗药物环磷酰胺的作用是最早的证据表明肠道菌群可以在癌症免疫学中发挥作用。环磷酰胺是常用于化学疗法的烷基化剂，调节免疫应答是环磷酰胺作用的关键机制之一，Viaud S等人 [<xref ref-type="bibr" rid="hanspub.39101-ref39">39</xref>] 研究表明了环磷酰胺改变了小肠中微生物群的组成，并诱导选定的革兰阳氏菌种向次级淋巴器官转移，进而刺激Th17和Th1的免疫反应，pTh17细胞的过继转移部分恢复了环磷酰胺的抗肿瘤功效，证明了肠道菌群有助于塑造抗癌免疫反应 [<xref ref-type="bibr" rid="hanspub.39101-ref11">11</xref>]。Daill&#232;re R等人 [<xref ref-type="bibr" rid="hanspub.39101-ref40">40</xref>] 研究发现环磷酰胺能促进不同的革兰阳氏细菌控制肿瘤相关的效应致病的Th17细胞应答，主要是小肠奈瑟氏球菌和平肠球菌，可以诱导的肿瘤的治疗性免疫调节作用。</p><p>化疗失败是结直肠癌复发和预后不良的主要原因，有学者发现在结直肠癌患者中减少特定的肠道微生物可以提高他们对化疗的反应，减少癌症的复发，其中，核梭杆菌通过自噬活化在化学耐药中的作用已被证实。Yu T等人 [<xref ref-type="bibr" rid="hanspub.39101-ref41">41</xref>] 的研究表明核梭杆菌靶向TLR 4和MYD 88天然免疫信号以及特异的microRNAs激活自噬通路，改变结直肠癌的化疗反应，控制着结直肠癌的化学耐药性。肠道菌群在肿瘤患者化疗治疗过程中的作用是如今医学领域的热点，需要更多的临床实验支撑这一理论。</p></sec><sec id="s8_3"><title>4.3. 肠道菌群影响肿瘤放射治疗</title><p>放射疗法(Radiotherapy, RT)是一种公认的治疗性癌症治疗方法，具有较强的免疫调节作用。但放疗后，不同患者的肿瘤反应的差异很大，其预后效果也非常不稳定，有科学家认为肠道菌群可能与这种异质性的反应有关 [<xref ref-type="bibr" rid="hanspub.39101-ref42">42</xref>]。Cui M等人 [<xref ref-type="bibr" rid="hanspub.39101-ref43">43</xref>] 通过小鼠肿瘤模型，研究了昼夜节律对放射治疗的影响，并与相应的肠道菌群组成进行了比较，结果显示，正常12-h暗/12-h光周期小鼠的存活率显著高于不同周期小鼠(8-h暗/16-h光或16-h暗/8-h暗)，且其p &lt; 0.05，在统计学上有显著差异，提示这与不同时间段小鼠模型肠道菌群的改变有关，这可能是辐射抗药性机制的一部分。Blair IA等人 [<xref ref-type="bibr" rid="hanspub.39101-ref44">44</xref>] 同时采用B16-OVA黑色素瘤模型和TC-1型肺癌/宫颈癌模型(表达HPV E6/7)小鼠研究万古霉素对荷瘤小鼠的抗肿瘤作用，其研究结果表明万古霉素对荷瘤小鼠的抗肿瘤作用有明显的正向影响，但这依赖于肠道菌群的辅助作用，肠道菌群的改变可引起肿瘤微环境重塑，介导引流淋巴结抗原提呈增加，提高放射治疗抗肿瘤效果，且万古霉素是一种广泛使用的临床药物，具有相对安全的特点，这一研究提高了使用这种抗生素来增强放射治疗在癌症患者中的疗效的潜力。然而，肠道微生物群对放射治疗效果的直接影响还没有得到真正的证实，需要临床上进一步地验证 [<xref ref-type="bibr" rid="hanspub.39101-ref45">45</xref>]。</p></sec></sec><sec id="s9"><title>5. 展望</title><p>人体中，肠道含有的微生物数量以及种类最多，其与恶性肿瘤的发生、发展、治疗效果等密切相关 [<xref ref-type="bibr" rid="hanspub.39101-ref46">46</xref>]，但科学家们尽管在了解人类肠道微生物组成方面做出了巨大努力并取得了实质性进展，许多功能方面仍未得到解决。这在一定程度上可能是由于人类肠道微生物区系的复杂性，存在大量不可预测的宿主微生物以及缺乏适当的技术，很难准确地研究肠道菌群在肿瘤发生中的作用 [<xref ref-type="bibr" rid="hanspub.39101-ref47">47</xref>]。并且关于肠道菌群对肿瘤的治疗方法，包括化学疗法和放射疗法都具有较大的副作用，在临床上难以进一步开展研究 [<xref ref-type="bibr" rid="hanspub.39101-ref38">38</xref>]。上述存在的缺陷都为此后肠道菌群与肿瘤的研究指明了方向，我们需要努力研究这些复杂又精细的相互作用并加以阐明，力求在此基础上更好地利用菌群与机体的相互作用，从而研发更有效的策略用于肿瘤治疗，促进人类健康。</p></sec><sec id="s10"><title>文章引用</title><p>黎雨晴,杨兴玉,王未希,周芳美. 肠道菌群与肿瘤的相关研究进展Research Progress of Intestinal Flora and Tumor[J]. 微生物前沿, 2020, 09(04): 156-163. https://doi.org/10.12677/AMB.2020.94021</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.39101-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Keku Temitope, O., Dulal, S., Deveaux, A., Jovov, B. and Han, X.S. (2015) The Gastrointestinal Microbiota and Colorectal Cancer. American Journal of Physiology: Gastrointestinal and Liver Physiology, 308, G351-G363.  
&lt;br&gt;https://doi.org/10.1152/ajpgi.00360.2012</mixed-citation></ref><ref id="hanspub.39101-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Montalban-Arques, A. and Scharl, M. (2019) Intestinal Microbiota and Colorectal Carcinoma: Implications for Pathogenesis, Diagnosis, and Therapy. EBioMedicine, 48, 648-655. &lt;br&gt;https://doi.org/10.1016/j.ebiom.2019.09.050</mixed-citation></ref><ref id="hanspub.39101-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Konturek, P.C., Haziri, D., Brzozowski, T., et al. (2015) Emerging Role of Fecal Microbiota Therapy in the Treatment of Gastrointestinal and Extra-Gastrointestinal Diseases. Journal of Physiology and Pharmacology, 66, 483-491.</mixed-citation></ref><ref id="hanspub.39101-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Nayfach, S., Shi, Z.J., Seshadri, R., Pollard, K.S. and Kyrpides, N.C. (2019) New Insights from Uncultivated Genomes of the Global Human Gut Microbiome. Nature, 568, 505-510. &lt;br&gt;https://doi.org/10.1038/s41586-019-1058-x</mixed-citation></ref><ref id="hanspub.39101-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Marchesi, J.R., Adams, D.H., Fava, F., et al. (2015) The Gut Microbiota and Host Health: A New Clinical Frontier. Gut, 65, 330-339. &lt;br&gt;https://doi.org/10.1136/gutjnl-2015-309990</mixed-citation></ref><ref id="hanspub.39101-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Nagasaka, M., Sexton, R., Alhasan, R., Rahman, S., Azmi, A.S. and Sukari, A. (2020) Gut Microbiome and Response to Checkpoint Inhibitors in Non-Small Cell Lung Cancer: A Review. Critical Reviews in Oncology/Hematology, 145, Article ID: 102841. &lt;br&gt;https://doi.org/10.1016/j.critrevonc.2019.102841</mixed-citation></ref><ref id="hanspub.39101-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Ganal-Vonarburg, S.C. and Duerr, C.U. (2020) The Interaction of Intestinal Microbiota and Innate Lymphoid Cells in Health and Disease throughout Life. Immunology, 159, 39-51. &lt;br&gt;https://doi.org/10.1111/imm.13138</mixed-citation></ref><ref id="hanspub.39101-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">雷中利, 黄燕. 肠道菌群失调在肝癌发生、发展和预防、治疗中的研究进展[J]. 肿瘤药学, 2020, 10(1): 16-20.</mixed-citation></ref><ref id="hanspub.39101-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Ye, B.X., Stary, C.M., Li, X.J., et al. (2018) Engineering Chimeric Antigen Receptor-T Cells for Cancer Treatment. Molecular Cancer, 17, 32. &lt;br&gt;https://doi.org/10.1186/s12943-018-0814-0</mixed-citation></ref><ref id="hanspub.39101-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Shreiner, A.B., Kao, J.Y. and Young, V.B. (2015) The Gut Microbiome in Health and in Disease. Current Opinion in Gastroenterology, 31, 69-75. &lt;br&gt;https://doi.org/10.1097/MOG.0000000000000139</mixed-citation></ref><ref id="hanspub.39101-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Khan, M.A.W., Ologun, G., Arora, R., McQuade, J.L. and Wargo, J.A. (2020) Gut Microbiome Modulates Response to Cancer Immunotherapy. Digestive Diseases and Sciences, 65, 885-896. &lt;br&gt;https://doi.org/10.1007/s10620-020-06111-x</mixed-citation></ref><ref id="hanspub.39101-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Belcheva, A., Irrazabal, T., Robertson, S.J., et al. (2014) Gut Microbial Metabolism Drives Transformation of msh2-Deficient Colon Epithelial Cells. Cell, 158, 288-299. &lt;br&gt;https://doi.org/10.1016/j.cell.2014.04.051</mixed-citation></ref><ref id="hanspub.39101-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Singh, N., Gurav, A., Sivaprakasam, S., et al. (2014) Activation of Gpr109a, Receptor for Niacin and the Commensal Metabolite Butyrate, Suppresses Colonic Inflammation and Carcinogenesis. Immunity, 40, 128-139.  
&lt;br&gt;https://doi.org/10.1016/j.immuni.2013.12.007</mixed-citation></ref><ref id="hanspub.39101-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Dai, Z.W., Coker, O.O., Nakatsu, G., Wu, W.K.K., Zhao, L.Y., Chen, Z.G., Chan, F.K.L., Kristiansen, K., Sung, J.J.Y., Wong, S.H. and Yu, J. (2018) Multi-Cohort Analysis of Colorectal Cancer Metagenome Identified Altered Bacteria across Populations and Universal Bacterial Markers. Microbiome, 6, 70.</mixed-citation></ref><ref id="hanspub.39101-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Ridlon, J.M., Devendran, S., Alves, J.M., et al. (2019) The “in Vivo Lifestyle” of Bile Acid 7α-Dehydroxylating Bacteria: Comparative Genomics, Metatranscriptomic, and Bile Acid Metabolomics Analysis of a Defined Microbial Community in Gnotobiotic Mice. Gut Microbes, 11, 381-404. &lt;br&gt;https://doi.org/10.1080/19490976.2019.1618173</mixed-citation></ref><ref id="hanspub.39101-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Mizutani, S., Yamada, T. and Yachida, S. (2020) Significance of the Gut Microbiome in Multistep Colorectal Carcinogenesis. Cancer Science, 111, 766-773. &lt;br&gt;https://doi.org/10.1111/cas.14298</mixed-citation></ref><ref id="hanspub.39101-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Drewes, J.L., Housseau, F. and Sears, C.L. (2016) Sporadic Colorectal Cancer: Microbial Contributors to Disease Prevention, Development and Therapy. British Journal of Cancer, 115, 273-280. &lt;br&gt;https://doi.org/10.1038/bjc.2016.189</mixed-citation></ref><ref id="hanspub.39101-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Komorowski, A.S. and Pezo, R.C. (2020) Untapped “-omics”: The Microbial Metagenome, Estrobolome, and Their Influence on the Development of Breast Cancer and Response to Treatment. Breast Cancer Research and Treatment, 179, 287-300. &lt;br&gt;https://doi.org/10.1007/s10549-019-05472-w</mixed-citation></ref><ref id="hanspub.39101-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">陈菲, 梁婷婷, 吕铮, 李薇, 崔久嵬. 肠道微生态与肿瘤发生和发展关系的研究进展[J]. 肿瘤代谢与营养电子杂志, 2020, 7(1): 7-12.</mixed-citation></ref><ref id="hanspub.39101-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Wei, M.-Y., Shi, S., Liang, C., Meng, Q.-C., Hua, J., Zhang, Y.-Y., Liu, J., Zhang, B., Xu, J. and Yu, X.-J. (2019) The Microbiota and Microbiome in Pancreatic Cancer: More Influential than Expected. Molecular Cancer, 18, Article No. 97. &lt;br&gt;https://doi.org/10.1186/s12943-019-1008-0</mixed-citation></ref><ref id="hanspub.39101-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Brennan, C.A. and Garrett, W.S. (2016) Gut Microbiota, Inflammation, and Colorectal Cancer. Annual Review of Microbiology, 70, 395-411. &lt;br&gt;https://doi.org/10.1146/annurev-micro-102215-095513</mixed-citation></ref><ref id="hanspub.39101-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Zmora, N., Levy, M., Pevsner-Fishcer, M. and Elinav, E. (2017) Inflammasomes and Intestinal Inflammation. Mucosal Immunology, 10, 865-883. &lt;br&gt;https://doi.org/10.1038/mi.2017.19</mixed-citation></ref><ref id="hanspub.39101-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Wei, M.Y., Shi, S., Liang, C., Meng, Q.C., Hua, J., Zhang, Y.Y., Liu, J., Zhang, B., Xu, J. and Yu, X.J. (2019) The Microbiota and Microbiome in Pancreatic Cancer: More Influential than Expected. Molecular Cancer, 18, 97.  
&lt;br&gt;https://doi.org/10.1186/s12943-019-1008-0</mixed-citation></ref><ref id="hanspub.39101-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Serra, N., Di Carlo, P., Gulotta, G., d’Arpa, F., Giammanco, A., Colomba, C., Melfa, G., Fasciana, T. and Sergi, C. (2018) Bactibilia in Women Affected with Diseases of the Biliary Tract and Pancreas. A STROBE Guidelines-Adherent Cross-Sectional Study in Southern Italy. Journal of Medical Microbiology, 67, 1090-1095.  
&lt;br&gt;https://doi.org/10.1099/jmm.0.000787</mixed-citation></ref><ref id="hanspub.39101-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Brennan, C.A. and Garrett, W.S. (2016) Gut Microbiota, Inflammation, and Colorectal Cancer. Annual Review of Microbiology, 70, 395-411. &lt;br&gt;https://doi.org/10.1146/annurev-micro-102215-095513</mixed-citation></ref><ref id="hanspub.39101-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Parkin, D.M. (2006) The Global Health Burden of Infection-Associated Cancers in the Year 2002. International Journal of Cancer, 118, 3030-3044. &lt;br&gt;https://doi.org/10.1002/ijc.21731</mixed-citation></ref><ref id="hanspub.39101-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Kostic, A.D., Chun, E., Robertson, L., Glickman, J.N., Gallini, C.A., Michaud, M., Clancy, T.E., Chung, D.C., Lochhead, P., Hold, G.L., El-Omar, E.M., Brenner, D., Fuchs, C.S., Meyerson, M. and Garrett, W.S. (2013) Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment. Cell Host Microbe, 14, 207-215. &lt;br&gt;https://doi.org/10.1016/j.chom.2013.07.007</mixed-citation></ref><ref id="hanspub.39101-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Gagnière, J., Raisch, J., Veziant, J., et al. (2016) Gut Microbiota Imbalance and Colorectal Cancer. World Journal of Gastroenterology, 22, 501-518. &lt;br&gt;https://doi.org/10.3748/wjg.v22.i2.501</mixed-citation></ref><ref id="hanspub.39101-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Uribe-Herranz, M., Rafail, S., Beghi, S., Gil-de-Gómez, L., Verginadis, I., Bittinger, K., Pustylnikov, S., Pierini, S., Perales-Linares, R., Blair, I.A., Mesaros, C.A., Snyder, N.W., Bushman, F., Koumenis, C. and Facciabene, A. (2020) Gut Microbiota Modulate Dendritic Cell Antigen Presentation and Radiotherapy-Induced Antitumor Immune Response. Journal of Clinical Investigation, 130, 466-479. &lt;br&gt;https://doi.org/10.1172/JCI124332</mixed-citation></ref><ref id="hanspub.39101-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, J. and Boutros, M. (2020) JNK-Dependent Intestinal Barrier Failure Disrupts Host-Microbe Homeostasis during Tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 117, 9401-9412.  
&lt;br&gt;https://doi.org/10.1073/pnas.1913976117</mixed-citation></ref><ref id="hanspub.39101-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Wu, S., Rhee, K.J., Zhang, M., Franco, A. and Sears, C.L. (2007) Bacteroides fragilis Toxin Stimulates Intestinal Epithelial Cell Shedding and Gamma-Secretase-Dependent E-Cadherin Cleavage. Journal of Cell Science, 120, 1944-1952.  
&lt;br&gt;https://doi.org/10.1242/jcs.03455</mixed-citation></ref><ref id="hanspub.39101-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Baffy, G. (2020) Gut Microbiota and Cancer of the Host: Colliding Interests. Advances in Experimental Medicine and Biology, 1219, 93-107. &lt;br&gt;https://doi.org/10.1007/978-3-030-34025-4_5</mixed-citation></ref><ref id="hanspub.39101-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">刘光峨, 马虎. 非小细胞肺癌免疫治疗相关生物标记物的研究进展[J]. 山东医药, 2020, 60(13): 100-103.</mixed-citation></ref><ref id="hanspub.39101-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Gopalakrishnan, V., Helmink, B.A., Spencer, C.N., Reuben, A. and Wargo, J.A. (2018) The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. Cancer Cell, 33, 570-580.  
&lt;br&gt;https://doi.org/10.1016/j.ccell.2018.03.015</mixed-citation></ref><ref id="hanspub.39101-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Iida, N., Dzutsev, A., Stewart, C.A., Smith, L., Bouladoux, N., Weingarten, R., Molina, D.A., Salcedo, R., Back, T., Cramer, S., Dai, R.M., Kiu, H., Cardone, M., Naik, S., Patri, A.K., Wang, E., Marincola, F.M., Frank, K.M., Belkaid, Y., Trinchieri, G. and Goldszmid, R.S. (2013) Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment. Science, 342, 967-970. &lt;br&gt;https://doi.org/10.1126/science.1240527</mixed-citation></ref><ref id="hanspub.39101-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Gopalakrishnan, V., Spencer, C.N., Nezi, L., et al. (2018) Gut Microbiome Modulates Response to Anti-PD-1 Immunotherapy in Melanoma Patients. Science, 359, 97-103.</mixed-citation></ref><ref id="hanspub.39101-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Vétizou, M., Pitt, J.M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M.P., Duong, C.P., Poirier-Colame, V., Roux, A., Becharef, S., Formenti, S., Golden, E., Cording, S., Eberl, G., Schlitzer, A., Ginhoux, F., Mani, S., Yamazaki, T., Jacquelot, N., Enot, D.P., Bérard, M., Nigou, J., Opolon, P., Eggermont, A., Woerther, P.L., Chachaty, E., Chaput, N., Robert, C., Mateus, C., Kroemer, G., Raoult, D., Boneca, I.G., Carbonnel, F., Chamaillard, M. and Zitvogel, L. (2015) Anticancer Immunotherapy by CTLA-4 Blockade Relies on the Gut Microbiota. Science, 350, 1079-1084. &lt;br&gt;https://doi.org/10.1126/science.aad1329</mixed-citation></ref><ref id="hanspub.39101-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Ma, W., Mao, Q., Xia, W., Dong, G., Yu, C. and Jiang, F. (2019) Gut Microbiota Shapes the Efficiency of Cancer Therapy. Frontiers in Microbiology, 10, 1050. &lt;br&gt;https://doi.org/10.3389/fmicb.2019.01050</mixed-citation></ref><ref id="hanspub.39101-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., et al. (2013) The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide. Science, 342, 971-976.  
&lt;br&gt;https://doi.org/10.1126/science.1240537</mixed-citation></ref><ref id="hanspub.39101-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Daillère, R., Vétizou, M., Waldschmitt, N., Yamazaki, T., Isnard, C., Poirier-Colame, V., et al. (2016) Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. Immunity, 45, 931-943. &lt;br&gt;https://doi.org/10.1016/j.immuni.2016.09.009</mixed-citation></ref><ref id="hanspub.39101-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Yu, T., Guo, F., Yu, Y., Sun, T., Ma, D., Han, J., Qian, Y., Kryczek, I., Sun, D., Nagarsheth, N., Chen, Y., Chen, H., Hong, J., Zou, W. and Fang, J.Y. (2017) Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy. Cell, 170, 548-563. &lt;br&gt;https://doi.org/10.1016/j.cell.2017.07.008</mixed-citation></ref><ref id="hanspub.39101-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Villéger, R., Lopès, A., Carrier, G., et al. (2019) Intestinal Microbiota: A Novel Target to Improve Anti-Tumor Treatment? International Journal of Molecular Sciences, 20, 4584.</mixed-citation></ref><ref id="hanspub.39101-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Cui, M., Xiao, H., Luo, D., Zhang, X., Zhao, S., Zheng, Q., Li, Y., Zhao, Y., Dong, J., Li, H., et al. (2016) Circadian Rhythm Shapes the Gut Microbiota Affecting Host Radiosensitivity. International Journal of Molecular Sciences, 17, 1786. &lt;br&gt;https://doi.org/10.3390/ijms17111786</mixed-citation></ref><ref id="hanspub.39101-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Blair, I.A., Mesaros, C.A., Snyder, N.W., Bushman, F., Koumenis, C. and Facciabene, A. (2020) Gut Microbiota Modulate Dendritic Cell Antigen Presentation and Radiotherapy-Induced Antitumor Immune Response. Journal of Clinical Investigation, 130, 466-479. &lt;br&gt;https://doi.org/10.1172/JCI124332</mixed-citation></ref><ref id="hanspub.39101-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Hekmatshoar, Y., Saadat, Y.R., Khatibi, S.M.H., Ozkan, T., Vahed, F.Z., Nariman-Saleh-Fam, Z., Gargari, B.P., Sunguroglu, A. and Vahed, S.Z. (2019) The Impact of Tumor and Gut Microbiotas on Cancer Therapy: Beneficial or Detrimental? Life Sciences, 233, Article ID: 116680. &lt;br&gt;https://doi.org/10.1016/j.lfs.2019.116680</mixed-citation></ref><ref id="hanspub.39101-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">薛越, 王青青. 肠道菌群与恶性肿瘤的研究进展[J]. 实用肿瘤杂志, 2016, 31(1): 9-13.</mixed-citation></ref><ref id="hanspub.39101-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Gensollen, T., Iyer, S.S., Kasper, D.L. and Blumberg, R.S. (2016) How Colonization by Microbiota in Early Life Shapes the Immune System. Science, 352, 539-544. &lt;br&gt;https://doi.org/10.1126/science.aad9378</mixed-citation></ref></ref-list></back></article>